Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

Overview

Journal Front Pharmacol

Date 2016 Nov 3

PMID 27803666

Citations 139

Authors

John P M Finberg

Jose M Rabey

Affiliations

Soon will be listed here.

Abstract

Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which substrates and inhibitor molecules are metabolized, or inhibit metabolism of substrates, respectively. Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clinical use has been limited by their side effect of potentiation of the cardiovascular effects of dietary amines ("cheese effect"). A number of reversible MAO-A inhibitors which are devoid of cheese effect have been described in the literature, but only one, moclobemide, is currently in clinical use. The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clinically in treatment of Parkinson's disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious. Modification of the pharmacokinetic characteristics of selegiline by transdermal administration has led to the development of a new drug form for treatment of depression. The clinical potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.

Citing Articles

Flavonoids and Saponins from Two Species ( Asch. and - L.)-Preliminary Evaluation for hMAO-A/B, Neuroprotective Activity, and Validated UHPLC-HRMS Quantification of Ethanolic Extract from .

Kondeva-Burdina M, Panayotova D, Nedialkov P, Kokanova-Nedialkova Z Molecules. 2025; 30(5).

PMID: 40076286 PMC: 11901915. DOI: 10.3390/molecules30051061.

Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.

Buneeva O, Medvedev A Int J Mol Sci. 2025; 26(3).

PMID: 39941014 PMC: 11818313. DOI: 10.3390/ijms26031248.

Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer's disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitors.

Guerguer F, Rossafi B, Abchir O, Raouf Y, Albalushi D, Samadi A PLoS One. 2025; 20(1):e0317261.

PMID: 39883631 PMC: 11781659. DOI: 10.1371/journal.pone.0317261.

Moroccan natural products for multitarget-based treatment of Alzheimer's disease: A computational study.

Guerguer F, Bouribab A, Karim E, Khedraoui M, Amegrissi F, Raouf Y PLoS One. 2025; 20(1):e0313411.

PMID: 39820594 PMC: 11737685. DOI: 10.1371/journal.pone.0313411.

Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration.

Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P J Neural Transm (Vienna). 2024; 132(3):387-406.

PMID: 39621110 DOI: 10.1007/s00702-024-02866-z.

References

Coyle J, Snyder S . Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science. 1969; 166(3907):899-901. DOI: 10.1126/science.166.3907.899. View

Reichmann H, Sommer U, Fuchs G, Hefter H, Mark G, Muller T . Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease. J Neurol. 2001; 247 Suppl 4:IV/40-1. DOI: 10.1007/pl00007776. View

Denney R, Denney C . An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B. Pharmacol Ther. 1985; 30(3):227-58. DOI: 10.1016/0163-7258(85)90050-6. View

Baker G, Wong J, Yeung J, Coutts R . Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord. 1991; 21(3):207-11. DOI: 10.1016/0165-0327(91)90041-p. View

Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R . Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006; 66(8):1200-6. DOI: 10.1212/01.wnl.0000204007.46190.54. View

Clarke A, Brewer F, Johnson E, Mallard N, Hartig F, Taylor S . A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna). 2003; 110(11):1241-55. DOI: 10.1007/s00702-003-0036-4. View

Heijnen W, De Fruyt J, Wierdsma A, Sienaert P, Birkenhager T . Efficacy of Tranylcypromine in Bipolar Depression: A Systematic Review. J Clin Psychopharmacol. 2015; 35(6):700-5. DOI: 10.1097/JCP.0000000000000409. View

Jenner P, Langston J . Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord. 2011; 26(13):2316-23. DOI: 10.1002/mds.23926. View

. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View

10.

Naylor G, Smith A, Connelly P . A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry. 1987; 22(5):657-9. DOI: 10.1016/0006-3223(87)90194-6. View

11.

Minders C, Petzer J, Petzer A, Lourens A . Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg Med Chem Lett. 2015; 25(22):5270-6. DOI: 10.1016/j.bmcl.2015.09.049. View

12.

Winger G, Yasar S, Negus S, Goldberg S . Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther. 1994; 56(6 Pt 2):774-80. DOI: 10.1038/clpt.1994.208. View

13.

Churchyard A, Mathias C, Boonkongchuen P, Lees A . Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 63(2):228-34. PMC: 2169684. DOI: 10.1136/jnnp.63.2.228. View

14.

Elsworth J, Sandler M, Lees A, Ward C, STERN G . The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J Neural Transm. 1982; 54(1-2):105-10. DOI: 10.1007/BF01249283. View

15.

Wang L, Esteban G, Ojima M, Bautista-Aguilera O, Inokuchi T, Moraleda I . Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur J Med Chem. 2014; 80:543-61. DOI: 10.1016/j.ejmech.2014.04.078. View

16.

Gal S, Zheng H, Fridkin M, Youdim M . Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem. 2005; 95(1):79-88. DOI: 10.1111/j.1471-4159.2005.03341.x. View

17.

Thebault J, Guillaume M, Levy R . Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2005; 24(10):1295-305. DOI: 10.1592/phco.24.14.1295.43156. View

18.

Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H . Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(5):841-5. DOI: 10.1016/S0278-5846(03)00117-9. View

19.

Myllyla V, Sotaniemi K, Hakulinen P, Maki-Ikola O, Heinonen E . Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study. Acta Neurol Scand. 1997; 95(4):211-8. DOI: 10.1111/j.1600-0404.1997.tb00101.x. View

20.

Blob L, Sharoky M, Campbell B, Kemper E, Gilmor M, Vandenberg C . Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr. 2006; 12(1):25-34. DOI: 10.1017/s1092852900020496. View